The benefits of many elective nonhepatic surgeries outweigh the risks for select patients with compensated cirrhosis, but those at high risk for poor surgical outcomes should continue to seek ...

Current guidelines recommend 5 to 7 days of broad-spectrum antibiotic prophylaxis for upper gastrointestinal bleeding in patients with cirrhosis. In a systematic review and meta-analysis, shorter ...

Among hospitalized patients with cirrhosis, a machine learning (ML) model enhanced mortality prediction compared with traditional methods and was consistent across country income levels in a large ...

In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...

Cirrhosis is the result of long-term liver injury where healthy tissue is replaced with scar tissue (fibrosis). Common causes of cirrhosis include alcohol use disorder (AUD), nonalcoholic fatty liver ...

Alcoholic cirrhosis is the severe, final stage of alcohol-associated liver disease, resulting from long-term heavy alcohol consumption. The disease involves permanent scarring of the liver, which ...

MASH significantly contributes to increased deaths and DALYs in the Americas, necessitating targeted public health policies. Despite declining hepatitis B-related liver disease, mortality from alcohol ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver-related ...

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure. The risk of ...